⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
TWEAK/Fn14 Targeting
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-14 — Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.: Aged-mouse AAV9 TWEAK knockdown (injections at 15 and 17 months, readout at 18 months) plus lentiviral silencing in DEX-treated C2C12 myotubes raised SIRT1/PGC-1α/p-AMPK, lowered mitochondrial ROS and inflammatory cytokines via p38 MAPK suppression, and attenuated age-related muscle mass loss — but forelimb grip strength did not significantly improve. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.
14-aug-2026
novelty 3
per-area 3
strengthens